The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial.

Hang Shu,Yaqin Dong,Zhonghua Xu,Linghui Cheng,Yin Lv,Weiwei Luo,Lei Xu,Haochen Zhu

doi:10.3389/fonc.2021.723193

Abstract

ObjectiveTo investigate the short-term efficacy and safety of Endostar combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical squamous cell carcinoma (LACSC).MethodsA total of 91 patients with LACSC admitted to the First Affiliated Hospital of Anhui Medical University from June 2019 to December 2020 were randomly assigned to either the experimental group (n = 48) or control group (n = 43). The control group received radiotherapy for cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT), and the experimental group received Endostar continuous intravenous infusion of anti-angiogenic therapy plus CCRT. The short-term efficacy, common clinical indicators, tumor indicators, changes in serum vascular endothelial growth factor-A (VEGF-A), and the occurrence of adverse events (AEs) were explored after treatment.ResultsCompared with the control group, the complete response (CR) rate in the experimental group was significantly increased (83.33% vs 65.12%, P < 0.05). Both routine indicators and tumor indicators in the two groups were significantly decreased compared to before treatment. Compared with the control group, patients in the experimental group had higher incidences of neutropenia, hypertension, and infection, but lower incidence of nausea. After treatment, the serological expression of VEGF-A was significantly decreased in both groups.ConclusionEndostar combined with CCRT in the treatment of LACSC can further improve the efficacy of CR rate and significantly reduce serum tumor indicators and VEGF-A levels, with mild and controllable AEs. Endostar combined with CCRT is expected to be a new treatment regimen for LACSC.

Highlights

Cervical cancer is a prevalent malignancy in women, ranking as the fourth most frequently diagnosed cancer and the leading cause of cancer death in women worldwide [1]
Endostar combined with concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced cervical squamous cell carcinoma (LACSC) can further improve the efficacy of complete response (CR) rate and significantly reduce serum tumor indicators and Endostar + CCRT in LACSC
Endostar combined with CCRT is expected to be a new treatment regimen for LACSC

Summary

Introduction

Cervical cancer is a prevalent malignancy in women, ranking as the fourth most frequently diagnosed cancer and the leading cause of cancer death in women worldwide [1]. Statistics show that there were approximately 570,000 new cases and 311,000 deaths globally in 2018 [1]. The prevention and screening techniques of cervical cancer have improved, patients are being diagnosed with cervical cancer at a younger age [2]. Cervical squamous cell carcinoma remains the major pathologic type, the HPV vaccine has led to a decrease in its incidence [3, 4]. In China, there are approximately 130,000 new cases and 53,000 deaths attributed cervical cancer each year [5]. Cervical cancer remains a serious threat to women’s health worldwide

Methods

Results

Discussion

Conclusion